14 November 2023
14 November 2023
The UK government has seen a cabinet reshuffle as the Prime Minister removed Steve Barclay as UK health secretary and replaced him with newcomer, Victoria Atkins.
GlobalData analysts predict sales of Takeda's Fruzaqla to reach $340m by 2028.
Novo Nordisk announced this week that its weight loss drug Wegovy reduces the risk of major cardiovascular events by 20%.
As per the company, the candidate THIO is the only direct telomere-targeting agent currently in clinical development.
Bylvay is the first therapy to receive approval in the region to treat pruritus in PFIC patients in this age group.
Legend Biotech is entitled to receive up to $1.01bn from Novartis in milestone payments.
The company will utilise the funding to support the clinical development of VTx-002 for ALS treatment.
Heqet Therapeutics and Ethris have collaborated to develop RNA-based therapeutics to treat cardiovascular conditions.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
As PD therapy currently centers on symptomatic treatment, the need for DMTs is one of the greatest unmet needs. Several companies within the late-stage PD pipeline are developing drugs that target PD via novel MOAs. Targeting α-synuclein and other neurotoxic proteins is a key strategy in the late-stage pipeline for DMTs. However, the lack of validated predictive biomarkers of PD progression have made the development of DMTs and neuroprotective agents challenging.
Give your business an edge with our leading industry insights.
